To Determine The Financial Imapct of Introducing Sc Rituximab (MABTHERA) vs. Currently used iv rituximab (MABTHERA) on The Budgets of Different Hospitals Across The Kingdom of Saudi Arabia (KSA)
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.152
https://www.valueinhealthjournal.com/article/S1098-3015(17)30486-2/fulltext
Title :
To Determine The Financial Imapct of Introducing Sc Rituximab (MABTHERA) vs. Currently used iv rituximab (MABTHERA) on The Budgets of Different Hospitals Across The Kingdom of Saudi Arabia (KSA)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30486-2&doi=10.1016/j.jval.2017.08.152
First page :
A424
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
132